Accessibility Tools

Currently there are two Phase 2 trials open to enrollment for GEO-CM04S1, a next generation Covid-19 vaccine. Please visit Pipeline for more information.

Innovations in Immunology

GeoVax is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. 

 

Our lead program in oncology is Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. Our lead infectious disease program is CM04S1, a next-generation Covid-19 vaccine targeting high-risk immunocompromised patient populations, currently in two Phase 2 clinical trials.
SUBSCRIBE FOR UPDATES FROM GEOVAX
Register to receive email alerts for GeoVax press releases
Copyright © GeoVax 2024. All Rights Reserved.

Search